Concepedia

Derek Wiswell

DW

14

Publications

1.4K

Citations

13

H-Index

2004

Active since

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Derek Wiswell is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, drug discovery, and pharmacology.

Top concepts

Publications per year

2004–2020

14

Publications

14

Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor

David Parry, Timothy J. Guzi, Nicole R. Davis et al. · Molecular Cancer Therapeutics · 2010 · 553 citations · Full text

, , +16

Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-Dependent Kinases

Kamil Paruch, Michael P. Dwyer, Carmen Álvarez et al. · ACS Medicinal Chemistry Letters · 2010 · 174 citations · Full text

, , +21

Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening

Timothy J. Guzi, Kamil Paruch, Michael P. Dwyer et al. · Molecular Cancer Therapeutics · 2011 · 170 citations · Full text

Omomyc Reveals New Mechanisms To Inhibit the MYC Oncogene

Mark J. Demma, Claudio Mapelli, Angie Sun et al. · Molecular and Cellular Biology · 2019 · 88 citations · Full text

Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: A template-based approach—Part 2

Marc Labroli, Kamil Paruch, Michael P. Dwyer et al. · Bioorganic & Medicinal Chemistry Letters · 2010 · 74 citations · Full text

, , +9

Rows per page

1–5 of 14